<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">BMC Psychiatry</journal-id><journal-title-group><journal-title>BMC Psychiatry</journal-title></journal-title-group><issn pub-type="epub">1471-244X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28302084</article-id><article-id pub-id-type="pmc">5356401</article-id><article-id pub-id-type="publisher-id">1255</article-id><article-id pub-id-type="doi">10.1186/s12888-017-1255-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effectiveness of EMDR in patients with substance use disorder and comorbid PTSD: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sch&#x000e4;fer</surname><given-names>Ingo</given-names></name><address><email>i.schaefer@uke.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chuey-Ferrer</surname><given-names>Laycen</given-names></name><address><email>lferrer@ahg.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hofmann</surname><given-names>Arne</given-names></name><address><email>arnehofmann@emdr.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lieberman</surname><given-names>Peter</given-names></name><address><email>p.liebermann@netcologne.de</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mainusch</surname><given-names>G&#x000fc;nter</given-names></name><address><email>gmainusch@ahg.de</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2834-8047</contrib-id><name><surname>Lotzin</surname><given-names>Annett</given-names></name><address><phone>+49-40-7410-55356</phone><email>a.lotzin@uke.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution>Department of Psychiatry and Psychotherapy, </institution><institution>University Medical Center Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff2"><label>2</label>Center for Interdisciplinary Addiction Research, Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, University of Hamburg, Martinistr. 52, Hamburg, D-20246 Germany </aff><aff id="Aff3"><label>3</label>AHG Clinic Dormagen, Dormagen, Germany </aff><aff id="Aff4"><label>4</label>EMDR-Institute Germany, Bergisch Gladbach, Germany </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>95</elocation-id><history><date date-type="received"><day>8</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based treatment for PTSD. However, it is unclear whether EMDR shows the same effectiveness in patients with substance use disorders (SUD) and comorbid PTSD. In this trial, we examine the effectiveness of EMDR in reducing PTSD symptoms in patients with SUD and PTSD.</p></sec><sec><title>Methods/Design</title><p>We conduct a single-blinded RCT among 158 patients with SUD and comorbid PTSD admitted to a German addiction rehabilitation center specialized for the treatment of patients with SUD and comorbid PTSD. Patients are randomized to receive either EMDR, added to SUD rehabilitation and non-trauma-focused PTSD treatment (TAU), or TAU alone. The primary outcome is change from baseline in PTSD symptom severity as measured by the Clinician-Administered PTSD Scale at 6-month follow-up. Secondary outcomes are change from baseline in substance use, addiction-related problems, depressive symptoms, dissociative symptoms, emotion dysregulation and quality of life. Assessments are carried out by blinded raters at admission, at end of treatment, and at 3- and 6-month follow-up. We expect that EMDR plus TAU will be more effective in reducing PTSD symptoms than TAU alone. Mixed models will be conducted using an intention-to-treat and per-protocol approach.</p></sec><sec><title>Discussion</title><p>This study aims to expand the knowledge about the effectiveness of EMDR in patients with SUD and comorbid PTSD. The expected finding of the superiority of EMDR in reducing PTSD symptoms compared to non-trauma-focused PTSD treatment may enhance the use of trauma-focused treatment approaches for patients with SUD and co-morbid PTSD.</p></sec><sec><title>Trial registration</title><p>German Clinical Trials Register: <ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&#x00026;TRIAL_ID=DRKS00009007">DRKS00009007</ext-link>; U1111-1172-9213. Retrospectively registered 01 Juni 2016.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Posttraumatic stress disorder</kwd><kwd>Alcohol</kwd><kwd>Substance abuse</kwd><kwd>Addiction</kwd><kwd>Comorbidity</kwd><kwd>Eye movement desensitization and reprocessing</kwd><kwd>Trauma-focused treatment</kwd><kwd>Exposure-based treatment</kwd><kwd>Psychotherapy outcome research</kwd></kwd-group><funding-group><award-group><funding-source><institution>Society of Rehabilitation Sciences North Rhine-Westphalia</institution></funding-source><award-id>GfR13007/623-18</award-id><principal-award-recipient><name><surname>Sch&#x000e4;fer</surname><given-names>Ingo</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>European EMDR Society</institution></funding-source><award-id>NA</award-id><principal-award-recipient><name><surname>Sch&#x000e4;fer</surname><given-names>Ingo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Up to 45% of the patients with SUD experience comorbid PTSD [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], indicating a clear need for PTSD treatment in this population. Although the importance of comorbid PTSD in the treatment of patients with SUD has been recognized [<xref ref-type="bibr" rid="CR4">4</xref>], most SUD inpatient rehabilitation centers in Germany do not offer integrated treatment for SUD and PTSD. When an integrated treatment is offered, non-trauma-focused interventions are predominantly used to address PTSD [<xref ref-type="bibr" rid="CR5">5</xref>]. This current clinical practice in routine SUD healthcare is in contrast to the national and international guidelines [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>] that recommend trauma-focused treatment for PTSD, which clearly yields higher effect sizes compared with non-trauma-focused approaches. However, the evidence base of these guidelines is built on trials in which patients with PTSD and comorbid SUD have been almost continuously excluded [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p>First evidence exists that trauma-focused treatments, such as prolonged exposure [<xref ref-type="bibr" rid="CR11">11</xref>], trauma-focused imaginal exposure [<xref ref-type="bibr" rid="CR12">12</xref>] and structured writing therapy [<xref ref-type="bibr" rid="CR13">13</xref>], may also be effective in patients with PTSD and comorbid SUD in reducing PTSD symptoms, although the evidence is not consistent [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. This trials also found that trauma-focused interventions for patients with SUD and comorbid PTSD could be applied securely without compromising substance use outcomes [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. This is an important result, because clinicians may hesitate to use trauma-focused therapy for patients with SUD and comorbid PTSD, because they might believe that eliciting intense emotions related to the traumatic event during trauma-focused treatment may increase the risk for relapse [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. EMDR is another trauma-focused treatment that has been shown to be effective in patients with PTSD alone [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. So far, no RCT has been conducted that examined whether EMDR is effective in reducing PTSD symptoms in patients with SUD and comorbid PTSD.</p><p>Trauma-focused PTSD treatment among patients with SUD may also effectively reduce SUD symptoms [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Patients with PTSD and SUD report higher levels of craving in response to trauma-related cues [<xref ref-type="bibr" rid="CR21">21</xref>] than patients with PTSD. Therefore, these patients might be more likely to use substances to regulate negative affective states associated with PTSD [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. If negative affective states related to PTSD could be effectively reduced by trauma-focused treatment, SUD symptoms might also be reduced.</p><sec id="Sec2"><title>Research aims and hypothesis</title><p>The primary aim of this study is to investigate the effectiveness of EMDR, added to SUD rehabilitation and non-trauma-focused PTSD treatment (TAU), in reducing PTSD symptom severity at 6-month follow-up compared with TAU alone in patients with SUD and comorbid PTSD. We hypothesize that EMDR combined with TAU will lead to a significantly greater reduction of PTSD symptoms than TAU alone, when comparing PTSD symptoms from baseline to 6-month follow-up. As secondary outcomes, we examine the effectiveness of EMDR on substance use-related outcomes, depressive symptoms, dissociative symptoms, emotion dysregulation and quality of life. If this study shows that EMDR can be used effectively in patients with SUD and comorbid PTSD, the results of this RCT might encourage a more frequent use of evidence-based trauma-focused treatments for patients with SUD and comorbid PTSD.</p></sec></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Design and study setting</title><p>This study is a rater-blinded 2-arms RCT. Assessments are scheduled pre-treatment (T0), post-treatment (T1), at 3-month (T2) and at 6-month (T3) follow-up. Participants are randomly assigned to either the EMDR plus TAU group or the TAU group. Data is assessed at an inpatient rehabilitation center in Germany (AHG Clinic Dormagen). This center is specialized for the treatment of patients with SUD (primarily alcohol use disorders) and comorbid PTSD. The study is coordinated by a research team of the Center for Interdisciplinary Addiction Research (CIAR), University Medical Center Hamburg-Eppendorf, Germany. The coordinating site is responsible for the study design, the training of the personnel involved in the data collection, the preparation and supply of all study documents, study monitoring, study supervision, data management and analysis, and reporting of the study results.</p></sec><sec id="Sec5"><title>Participants</title><p>We plan to recruit 158 adult patients with SUD and comorbid PTSD attending inpatient rehabilitation treatment from September 2015 to December 2017. Inclusion criteria are (1) age between 18 and 65&#x000a0;years; (2) DSM-5 diagnosis of a substance use disorder [<xref ref-type="bibr" rid="CR24">24</xref>]; (3) DSM-5 diagnosis of PTSD or subsyndromal PTSD (criteria A and B and at least one of the criteria C to E) [<xref ref-type="bibr" rid="CR18">18</xref>]; (4) capable to comprehend and speak German; (5) informed consent to participate in the study. Exclusion criteria are (1) severe dissociative symptoms according to the Dissociative Experience Scale [<xref ref-type="bibr" rid="CR25">25</xref>] (total score&#x02009;&#x0003e;&#x02009;40); (2) acute suicidality; (3) acute psychotic symptoms; and (4) severe cognitive impairments.</p></sec><sec id="Sec6"><title>Interventions</title><p>All patients included in this study participate in the usual treatment (TAU) of the SUD rehabilitation center provided for patients with SUD and comorbid PTSD. TAU includes SUD rehabilitation and non-trauma-focused PTSD treatment. TAU is present-focused and includes the provision of knowledge, techniques and skills to better cope with PTSD symptoms and to prevent SUD relapse (psychoeducation about PTSD and SUD; resource activation, e.g. establishing positive activities; imaginative exercises [<xref ref-type="bibr" rid="CR26">26</xref>]; acceptance- and mindfulness-oriented skills [<xref ref-type="bibr" rid="CR27">27</xref>]; elements of Seeking Safety [<xref ref-type="bibr" rid="CR28">28</xref>], non-trauma-focused CBT). A treatment protocol was created prior to the start of the study that defines the intervention elements of the non-trauma-focused treatment. No processing of traumatic memories takes place in the TAU condition.</p><p>All study participants receive two 90-min and two 60-min non-trauma-focused group therapy sessions per week. In addition to the non-trauma-focused group therapy, participants randomized to the TAU group additionally receive one 50-min individual non-trauma-focused therapy session per week; participants randomized to the EMDR group receive one 50-min individual EMDR session per week. During an EMDR session, the patient focuses on a traumatic experience while simultaneously focusing on an external bilateral stimulus [<xref ref-type="bibr" rid="CR29">29</xref>]. EMDR treatment follows standard EMDR protocols for processing memories of traumatic or stressful life events [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec7"><title>Measures</title><sec id="Sec8"><title>Diagnoses of SUD and PTSD</title><p>To assess DSM-5 diagnoses of SUD and PTSD, all patients receive a semi-structured face-to-face interview at baseline (T0). The diagnosis of SUD is confirmed using the SUD section of the International Diagnostic Checklists for DSM-IV (IDCL) [<xref ref-type="bibr" rid="CR31">31</xref>], adapted according to the changed SUD criteria in DSM-V. The IDCL is an established method for the assessment of psychiatric diagnoses. Studies have indicated good clinical practicability and satisfactory to excellent inter-rater and test-retest reliability [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p>The diagnosis of PTSD is confirmed using the Clinician-Administered PTSD Scale (CAPS) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] for DSM-V [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], which is an updated version of the CAPS for DSM-IV. The CAPS is considered the gold standard for PTSD assessment [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The psychometric properties of the CAPS-IV have been reviewed [<xref ref-type="bibr" rid="CR35">35</xref>] and indicate excellent convergent and discriminant validity, diagnostic utility, and sensitivity to clinical change.</p></sec><sec id="Sec9"><title>Primary outcome</title><p>The primary outcome, change from baseline in PTSD symptom severity, is assessed using the CAPS for DSM-V [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. The interviewer evaluates the severity of each of the 20 DSM-V PTSD symptoms, based on a combined evaluation of the frequency and intensity on Likert-type scales (0&#x02009;=&#x02009;asymptomatic, 1&#x02009;=&#x02009;mild/subthreshold, 2&#x02009;=&#x02009;moderate PTSD/above threshold, 3&#x02009;=&#x02009;severe/markedly increased, 4&#x02009;=&#x02009;extreme). The 20 DSM-5 PTSD symptom severity scores are then summed up to derive a total severity score, ranging from 0 to 80. A change of 15 points on the CAPS is considered clinically significant [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec10"><title>Seconday outcomes</title><p>Secondary outcomes include change from baseline in severity of substance use, addiction-related problems, dissociative symptoms, depressive symptoms, emotion dysregulation and quality of life (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Measures and assessment points used in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Measure</th><th>Assessment method</th><th>T0 Baseline</th><th>T1 Post treatment</th><th>T2 3&#x000a0;months</th><th>T3 6&#x000a0;months</th></tr></thead><tbody><tr><td>SUD diagnosis</td><td>IDCL [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td>interview</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>PTSD diagnosis</td><td>CAPS [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>interview</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>PTSD symptoms</td><td>CAPS [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>interview</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Early traumatic experiences</td><td>CTQ [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td>self-report</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Substance use</td><td>AUDIT [<xref ref-type="bibr" rid="CR37">37</xref>]/DUDIT [<xref ref-type="bibr" rid="CR40">40</xref>] TLFB [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td>interview</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Addiction-related problems</td><td>ASI-Lite [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td>interview</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Dissociative symptoms</td><td>DES [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td>self-report</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Depressive symptoms</td><td>BDI-II [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td>self-report</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Emotion dysregulation</td><td>DERS [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td>self-report</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Quality of life</td><td>SF-12 [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td>self-report</td><td>x</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Safety</td><td>SAE Report Form</td><td>self-report</td><td colspan="2">----------------</td><td>x</td><td>x</td></tr></tbody></table><table-wrap-foot><p>
<italic>Notes. IDCL</italic> International Diagnostic Checklists. <italic>CAPS</italic> Clinician-Administered PTSD Scale. <italic>CTQ</italic> Childhood Trauma Questionnaire. <italic>AUDIT</italic> Alcohol Use Disorders Identification Test. <italic>DUDIT</italic> Drug Use Disorders Identification Test. <italic>TLFB</italic> Timeline Follow Back. <italic>ASI-Lite</italic> Addiction Severity Index-Lite. <italic>DES</italic> Dissociative Experience Scale. <italic>BDI-II</italic> Beck Depression Inventory-II. <italic>DERS</italic> Difficulties in Emotion Regulation Scale. <italic>SF-12</italic> Short-Form 12-Item Health Survey. <italic>SAE</italic> Serious Adverse Event</p></table-wrap-foot></table-wrap>
</p><p>Change from baseline in severity of substance use is measured by the Alcohol Use Disorder Identification Test (AUDIT) [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] or the Drug Use Disorder Identification Test (DUDIT) [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], respectively, depending on the type of the patients&#x02019; primary substance dependence. As additional substance-related outcomes, the mean amount of substance use per day and the number of non-consuming days within the last month is measured with the Timeline Follow Back (TLFB) [<xref ref-type="bibr" rid="CR41">41</xref>]. Changes in addiction-related problems are assessed by the Addiction Severity Index-Lite (ASI-Lite) [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>Change in dissociative symptoms (Dissociative Experiences Scale, DES) [<xref ref-type="bibr" rid="CR25">25</xref>], depressive symptoms (Beck Depression Inventory-II, BDI-II) [<xref ref-type="bibr" rid="CR43">43</xref>], emotion dysregulation (Difficulties in Emotion Regulation Scale, DERS) [<xref ref-type="bibr" rid="CR44">44</xref>] and quality of life (Short-Form 12-Item Health Survey, SF-12) [<xref ref-type="bibr" rid="CR45">45</xref>] are also assessed. The type and severity of early traumatic experiences are measured using the Childhood Trauma Questionnaire (CTQ) [<xref ref-type="bibr" rid="CR46">46</xref>]. Sociodemographic data of the patients are measured by an interview using a sheet designed according to the documentation standards for the evaluation of addiction treatment [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p>Serious Adverse Events (SAEs; hospitalization, life-threatening event, disability or permanent damage, death) are measured by SAE Reporting Forms (date; initials of reporting person; participant study number and participant date of birth; SAE description; start date and duration of event; action required; action with regard to intervention; date of last intervention session; causality to intervention or assessment).</p></sec></sec><sec id="Sec11"><title>Study procedure</title><p>At the patients&#x02019; admission to the rehabilitation center, a clinical psychologist informs the patient about the study and screens the patient according to the inclusion and exclusion study criteria. Patients that are potentially eligible for the study and consent to participate will receive the baseline assessment (T0) within the first days after admission (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). If all inclusion and no exclusion criteria are fulfilled, the patient will be randomized to one of the two study arms. Additional data assessments are conducted at end of treatment (T1), as well as at 3-months and 6-months follow-up (T2 and T3, respectively). The interviews at T0 and T1 are conducted face-to-face, the interviews at T2 and T3 are conducted by telephone. To promote participant retention and complete follow-up, participants will be contacted several times between the assessments. The coordinating study team monitors the study procedure and traces back potential Serious Adverse Events during the study.<fig id="Fig1"><label>Fig. 1</label><caption><p>Participant flow diagram</p></caption><graphic xlink:href="12888_2017_1255_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec12"><title>Sample size calculation</title><p>Based on the results of the power analysis of a first RCT examining the effects of a trauma-focused PTSD treatment plus usual substance use treatment vs. usual substance use treatment &#x0feff;alone&#x0feff; in patients with PTSD and SUD [<xref ref-type="bibr" rid="CR11">11</xref>], using the Clinician-Administered PTSD Scale (CAPS) as primary outcome, a sample size of 88 participants is required to achieve 80% power to detect a clinical significant difference of 15 points (SD&#x02009;=&#x02009;25) in PTSD symptoms at 6-months follow-up, using mixed models with a .05 &#x003b1;-level of significance. In line with the dropout rates reported in previous intervention studies using rehabilitation inpatients [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], a dropout rate of 40% is expected at 6-month follow-up. Consequently, we aim to include 158 participants in our study.</p></sec><sec id="Sec13"><title>Statistical analysis</title><p>Summary tables will be provided for all baseline, end of treatment and follow-up variables. Data will be summarized using frequency tables and descriptive statistics (mean, standard deviation, number and percentages of cases). Intention-to-treat and per-protocol analyses will be conducted for all outcomes. Missing data will be imputed using multiple imputation or a similar strategy.</p><p>To test the hypothesis that EMDR plus TAU will more greatly reduce PTSD symptoms than TAU alone, a linear mixed model will be calculated. Changes in PTSD symptom severity at 6-month follow-up as measured by the CAPS will be the primary outcome of the study and will be compared between the EMDR plus TAU and TAU group. The analysis will be adjusted for covariates that might be unbalanced between the groups (e.g., sex, type of trauma, treatment time spent in rehabilitation center), as well as for different baseline CAPS scores. The same procedure will be applied for secondary outcomes.</p></sec><sec id="Sec14"><title>Methods to protect against sources of bias</title><sec id="Sec15"><title>Randomization and allocation</title><p>All patients eligible for the study and providing written consent are randomized to an EMDR or a TAU group in a ratio of 1:1. The generation of the randomization sequence took place prior to the recruitment of participants and was conducted by a researcher of the coordinating site uninvolved in the data assessments of the study (AL). The list for the random assignment of patients to the two treatment arms was generated by the randomization software DatInf RandList Version 1.2 using permuted blocks of random sizes between 4 and 10. Each random number is separately stored in sequentially numbered, opaque and sealed envelopes. After the eligibility of a patient for the study has been ensured, the patient is included in the study and the next available randomization number is assigned to the patient in an ascending order.</p></sec><sec id="Sec16"><title>Blinding</title><p>Study personnel involved in the data assessment of the study are blinded to the patients&#x02019; treatment assignment. The clinical psychotherapists that deliver the study treatment are not blinded and are therefore uninvolved in the patients&#x02019; data assessments related to this study. Data analysts are blinded to group allocation.</p></sec><sec id="Sec17"><title>Treatment fidelity</title><p>All psychotherapists involved in this study regularly work as psychotherapists in the rehabilitation center at which the study is conducted. They were trained in SUD rehabilitation and non-trauma-focused PTSD treatment and completed the EMDR Basic Training program (see <ext-link ext-link-type="uri" xlink:href="http://www.emdr-europe.org/info.asp?CategoryID=83">http://www.emdr-europe.org/info.asp?CategoryID=83</ext-link>). All treatments are conducted in line with the respective treatment protocols (see description of interventions). All therapists are supervised by certified EMDR consultants or trainers of EMDR&#x000a0;Europe (LCF, PL, AH) during the treatment phase of the study.</p><p>Psychotherapists document the content of each individual treatment session in a treatment log, which is monitored by the coordinating site. Out of all individual treatment sessions, 15% randomly chosen videotaped sessions of each of the two treatment groups are rated for treatment fidelity (compliance with the treatment manual). EMDR treatment adherence is evaluated and monitored by certified EMDR consultants or trainers (LCF, PL, AH) using the EMDR Implementation Treatment Fidelity Scale [<xref ref-type="bibr" rid="CR50">50</xref>]. Therapist adherence for individual SUD rehabilitation and non-trauma-focused PTSD treatment is evaluated and monitored over the course of study by trained raters of the coordinating site.</p></sec><sec id="Sec18"><title>Data assessment fidelity</title><p>The personnel involved in data collection (psychology students with at least BSc level) received a 1-day training by the coordinating site prior to the start of the study. The coordinating site monitors the conduction of the data assessments and supervises (AL) the personnel involved in data collection throughout the study. 15% of the CAPS interviews are reassessed by a second interviewer to establish inter-rater reliability of the PTSD diagnosis and symptom severity. If reliability is low, the interviewers receive additional training. To improve data entry accuracy, all data sheets are entered by using a data scanner. Data entries are checked by data management personnel for correctness.</p></sec></sec><sec id="Sec19"><title>Ethical and safety issues</title><p>The Ethics Committee of the Medical Council of Hamburg (PV4853) and the Ethics Committee of the Medical Council of Nordrhein (2015233) approved the trial prior to the start of the study. Before patients are included in the study, they are informed about the aims and the design of the study including randomization and the possibility of ending their participation at any time without disadvantages. Potential study participants must provide written informed consent before they can be included in the study. Personal information about potential and enrolled participants will be collected and stored separately from other study data and will be only accessible for the assessors that contact the participants for data assessment. The study dataset does not include personal information and will be analyzed by the coordinating study site. Throughout the study, the standard safety procedures of the inpatient rehabilitation center at which the patients of this study are treated are followed. SAEs are continuously documented throughout the study. SAEs are reported to the coordinating site within 24&#x000a0;h. In case of an unexpected SAE (e.g., life-threatening event, permanent damage or death) over the course of the study, the coordinating site will alert the principal investigator (IS) who will report the SAE to the local ethics committee. The ethics committee and the study team will then decide in accordance with the best interest of the patient if the study procedures are continued or terminated.</p></sec></sec><sec id="Sec20"><title>Discussion</title><p>This is the first RCT that examines the effectiveness of EMDR combined with TAU (SUD rehabilitation and non-trauma-focused PTSD treatment), in reducing PTSD symptoms in patients with SUD and comorbid PTSD, compared with TAU alone. To test the effectiveness of EMDR within this patient group is crucial, because patients with SUD and comorbid PTSD have been excluded from most clinical trials of trauma-focused interventions for patients with PTSD so far [<xref ref-type="bibr" rid="CR51">51</xref>]. Consequently, there is limited evidence that EDMR is effective in this patient group. As a secondary outcome, we also examine the effectiveness of EMDR on substance use. As patients may use substances to regulate PTSD-related symptoms [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], it could be expected that trauma-focused treatment might also reduce SUD symptoms.</p><sec id="Sec21"><title>Strengths and limitations</title><p>A strength of this study is that we will be able to include a sufficient sample size in our study to detect group differences between the EMDR plus TAU and the TAU group. However, we expect a high drop-out rate in our sample&#x000a0;of patients with comorbid mental disorders. The expected high drop-out rate might complicate the interpretation of the study results. A strength of this study might be that the patients included in this study live in various parts of Germany, represent a great variety of their sociodemographic backgrounds and were exposed to different types of traumatic experiences. This may increase the generalizability of our results. On the other hand, we exclude patients that are younger than 18 or older than 65&#x000a0;years; don&#x02019;t speak German; present acute suicidal, psychotic or severe dissociative symptoms; or show severely cognitive impairment. The study findings might not be generalized to these populations of patients with SUD and PTSD.</p><p>In summary, the primary aim of this study is to investigate the effectiveness of EMDR, added to usual SUD rehabilitation and non-trauma-focused PTSD treatment (TAU), in reducing PTSD symptoms, compared with TAU alone. If this RCT proves that EMDR is effective in patients with SUD and comorbid PTSD, the results of this RCT may encourage a more frequent use of evidence-based trauma-focused approaches in routine treatment of patients with SUD and comorbid PTSD.</p></sec><sec id="Sec22"><title>Trial status</title><p>We are recruiting patients and started with data collection. The first patient was enrolled in September 2015.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p>Adverse events</p></def></def-item><def-item><term>ASI-Lite</term><def><p>Addiction Severity Index-Lite</p></def></def-item><def-item><term>AUDIT</term><def><p>Alcohol Use Disorders Identification Test</p></def></def-item><def-item><term>BDI-II</term><def><p>Beck Depression Inventory-II</p></def></def-item><def-item><term>CAPS</term><def><p>Clinician-Administered PTSD Scale</p></def></def-item><def-item><term>DERS</term><def><p>Difficulties in Emotion Regulation Scale</p></def></def-item><def-item><term>DES</term><def><p>Dissociative Experience Scale</p></def></def-item><def-item><term>DSM-V</term><def><p>Diagnostic and Statistical Manual of Mental Disorders</p></def></def-item><def-item><term>DUDIT</term><def><p>Drug Use Disorders Identification Test</p></def></def-item><def-item><term>EMDR</term><def><p>Eye Movement Desensitization and Reprocessing</p></def></def-item><def-item><term>IDCL</term><def><p>International Diagnostic Checklists</p></def></def-item><def-item><term>PTSD</term><def><p>Posttraumatic stress disorder</p></def></def-item><def-item><term>RCT</term><def><p>Randomized controlled trial</p></def></def-item><def-item><term>SAE</term><def><p>Serious Adverse Event</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SF-12</term><def><p>Short-Form 12-Item Health Survey</p></def></def-item><def-item><term>TAU</term><def><p>Treatment as usual</p></def></def-item><def-item><term>TLFB</term><def><p>Timeline Follow Back</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We greatly thank Jehanra Moriabadi, Helen Seeliger, Bella Liebig and Alexandra Smyth for preparing the study documents; Eike Neumann-Runde for setting up an online monitoring system, Lea Tichelb&#x000e4;cker for screening patients; Nina Lejeune, Alexandra Smyth, Marianne Haar and Julia Kraus for their tremendous efforts in the data collection; Isabell Liebig and Hannah Beckmann for supporting the study monitoring; Dr. Philipp Hiller for supervising the scanning of the data sheets and the plausibility checks; and Henriette Reichwald for conducting the data plausibility checks. We greatly thank all psychotherapists involved at any stage of the study that provide EMDR and/or usual treatment: Annika Deckers, Karin Heim, Silvia Hollweger, Elisabeth Mick, Christina Rohde, Marieke Sch&#x000fc;berl and Lea Tichelb&#x000e4;cker.</p><sec id="FPar1"><title>Funding</title><p>This study is supported by a grant from the Society of Rehabilitation Sciences North Rhine Westphalia, Germany (grant no. GfR13007/623-18, E-Mail: info@rehaforschung-nrw.de) and is co-funded by a grant from the European EMDR Society (E-Mail: info@emdr-europe.org). The study sponsors did not influence the study design, data collection, management, analysis, and interpretation of data; writing of the study protocol; or the decision to submit the study protocol for publication.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>IS is the PI of the trial and was primarily responsible for the design of the study. AL, LCF, AH and PL contributed to the study design. LCF supervises the study therapists. AL coordinates the trial and drafted the manuscript. IS, LCF, AH, PL and GM contributed to editing the manuscript and read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The study received a grant of 10.000 &#x020ac; by EMDRIA Europe. AH heads the EMDR-Institute Germany that trains in EMDR. He is a board member of the EMDR-Institute Germany. LCF is a board member of the EMDR-Institute Germany and an EMDR consultant. PL is a member of the EMDR-Institute Germany. He is treasurer of EMDR Europe. The remaining authors have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The Ethics Committee of the Medical Council of Hamburg (PV4853) and the Ethics Committee of the Medical Council of Nordrhein (2015233) approved the trial prior to the start of the study. Potential study participants must provide written informed consent before they can be included in the study. Before patients are included in the study, they are informed about the aims and the design of the study including randomization and the possibility of ending their participation at any time without disadvantages.</p></sec><sec id="FPar7"><title>Publisher's Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dore</surname><given-names>G</given-names></name><name><surname>Mills</surname><given-names>K</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Teesson</surname><given-names>M</given-names></name><name><surname>Farrugia</surname><given-names>P</given-names></name></person-group><article-title>Post-traumatic stress disorder, depression and suicidality in inpatients with substance use disorders</article-title><source>Drug Alcohol Rev</source><year>2012</year><volume>31</volume><fpage>294</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1111/j.1465-3362.2011.00314.x</pub-id><pub-id pub-id-type="pmid">21521385</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driessen</surname><given-names>M</given-names></name><name><surname>Schulte</surname><given-names>S</given-names></name><name><surname>Luedecke</surname><given-names>C</given-names></name><name><surname>Schaefer</surname><given-names>I</given-names></name><name><surname>Sutmann</surname><given-names>F</given-names></name><name><surname>Ohlmeier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Trauma and PTSD in patients with alcohol, drug, or dual dependence: a multi-center study</article-title><source>Alcohol Clin Exp Res</source><year>2008</year><volume>32</volume><fpage>481</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2007.00591.x</pub-id><pub-id pub-id-type="pmid">18215214</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>KL</given-names></name><name><surname>Teesson</surname><given-names>M</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>L</given-names></name></person-group><article-title>Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being</article-title><source>Am J Psychiatry</source><year>2006</year><volume>163</volume><fpage>652</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1176/ajp.2006.163.4.652</pub-id><pub-id pub-id-type="pmid">16585440</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Potthast N, Catani C. Trauma und Sucht: Implikationen f&#x000fc;r die Psychotherapie [trauma and addiction: implications for psychotherapy]. SUCHT. 2012;58:227&#x02013;35.</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Sch&#x000e4;fer I, Schulze C, Stubenvoll M. Psychotherapie bei Abh&#x000e4;ngigkeitserkrankungen und Posttraumatischer Belastungsst&#x000f6;rung [psychotherapy for substance use disorders and posttraumatic stress disorder]. SUCHT. 2011;57:353&#x02013;61.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Flatten</surname><given-names>G</given-names></name><name><surname>Gast</surname><given-names>U</given-names></name><name><surname>Hofmann</surname><given-names>A</given-names></name><name><surname>Knaevelsrud</surname><given-names>C</given-names></name><name><surname>Lampe</surname><given-names>A</given-names></name><name><surname>Liebermann</surname><given-names>P</given-names></name><etal/></person-group><source>Posttraumatische Belastungsst&#x000f6;rung: S3-Leitlinie und Quellentexte</source><year>2013</year><publisher-loc>Stuttgart</publisher-loc><publisher-name>Schattauer</publisher-name></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Collaborating Centre for Mental Health</collab></person-group><source>Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care</source><year>2005</year><publisher-loc>London</publisher-loc><publisher-name>Gaskell and the British Psychological Society</publisher-name></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Australian Center for Posttraumatic Health (ACPMH). Australian guidelines for the treatment of acute stress disorder &#x00026; posttraumatic stress disorder. Guidelines Appendices. Melbourne, VIC: ACPMH; 2013. Retrieved from <ext-link ext-link-type="uri" xlink:href="http://phoenixaustralia.org/resources/ptsd-guidelines/">http://phoenixaustralia.org/resources/ptsd-guidelines/</ext-link>.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>R</given-names></name><name><surname>Greene</surname><given-names>J</given-names></name><name><surname>Russ</surname><given-names>E</given-names></name><name><surname>Dutra</surname><given-names>L</given-names></name><name><surname>Westen</surname><given-names>D</given-names></name></person-group><article-title>A multidimensional meta-analysis of psychotherapy for PTSD</article-title><source>Am J Psychiatry</source><year>2005</year><volume>162</volume><fpage>214</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.162.2.214</pub-id><pub-id pub-id-type="pmid">15677582</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>BV</given-names></name><name><surname>Schnurr</surname><given-names>PP</given-names></name><name><surname>Mayo</surname><given-names>L</given-names></name><name><surname>Young-Xu</surname><given-names>Y</given-names></name><name><surname>Weeks</surname><given-names>WB</given-names></name><name><surname>Friedman</surname><given-names>MJ</given-names></name></person-group><article-title>Meta-analysis of the efficacy of treatments for posttraumatic stress disorder</article-title><source>J Clin Psychiatry</source><year>2013</year><volume>74</volume><fpage>e541</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.4088/JCP.12r08225</pub-id><pub-id pub-id-type="pmid">23842024</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>KL</given-names></name><name><surname>Teesson</surname><given-names>M</given-names></name><name><surname>Back</surname><given-names>SE</given-names></name><name><surname>Brady</surname><given-names>KT</given-names></name><name><surname>Baker</surname><given-names>AL</given-names></name><name><surname>Hopwood</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: a randomized controlled trial</article-title><source>JAMA J Am Med Assoc</source><year>2012</year><volume>308</volume><fpage>690</fpage><lpage>9</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>SF</given-names></name><name><surname>Stasiewicz</surname><given-names>PR</given-names></name><name><surname>Hughes</surname><given-names>PM</given-names></name><name><surname>Brimo</surname><given-names>ML</given-names></name></person-group><article-title>Trauma-focused imaginal exposure for individuals with comorbid posttraumatic stress disorder and alcohol dependence: revealing mechanisms of alcohol craving in a cue reactivity paradigm</article-title><source>Psychol Addict Behav</source><year>2006</year><volume>20</volume><fpage>425</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1037/0893-164X.20.4.425</pub-id><pub-id pub-id-type="pmid">17176177</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dam</surname><given-names>D</given-names></name><name><surname>Ehring</surname><given-names>T</given-names></name><name><surname>Vedel</surname><given-names>E</given-names></name><name><surname>Emmelkamp</surname><given-names>PM</given-names></name></person-group><article-title>Trauma-focused treatment for posttraumatic stress disorder combined with CBT for severe substance use disorder: a randomized controlled trial</article-title><source>BMC Psychiatry</source><year>2013</year><volume>13</volume><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-13-172</pub-id><pub-id pub-id-type="pmid">23782590</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foa</surname><given-names>EB</given-names></name><name><surname>Yusko</surname><given-names>DA</given-names></name><name><surname>McLean</surname><given-names>CP</given-names></name><name><surname>Suvak</surname><given-names>MK</given-names></name><name><surname>Bux</surname><given-names>DA</given-names></name><name><surname>Oslin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial</article-title><source>JAMA</source><year>2013</year><volume>310</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.8268</pub-id><pub-id pub-id-type="pmid">23925619</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGovern</surname><given-names>MP</given-names></name><name><surname>Lambert-Harris</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Meier</surname><given-names>A</given-names></name><name><surname>McLeman</surname><given-names>B</given-names></name><name><surname>Saunders</surname><given-names>E</given-names></name></person-group><article-title>A randomized controlled trial of treatments for co-occurring substance use disorders and post-traumatic stress disorder</article-title><source>Addiction</source><year>2015</year><volume>110</volume><fpage>1194</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1111/add.12943</pub-id><pub-id pub-id-type="pmid">25846251</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>CB</given-names></name><name><surname>Zayfert</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>E</given-names></name></person-group><article-title>A survey of psychologists&#x02019; attitudes towards and utilization of exposure therapy for PTSD</article-title><source>Behav Res Ther</source><year>2004</year><volume>42</volume><fpage>277</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0005-7967(03)00138-4</pub-id><pub-id pub-id-type="pmid">14975770</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najavits</surname><given-names>LM</given-names></name></person-group><article-title>Treatment for the dual diagnosis of posttraumatic stress and substance use disorders</article-title><source>Dir Addict Treat Prev</source><year>2004</year><volume>8</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regel</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>S</given-names></name></person-group><article-title>Review of post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care</article-title><source>Couns Psychother Res</source><year>2007</year><volume>7</volume><fpage>129</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1080/14733140701346156</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Back</surname><given-names>SE</given-names></name><name><surname>Brady</surname><given-names>KT</given-names></name><name><surname>Sonne</surname><given-names>SC</given-names></name><name><surname>Verduin</surname><given-names>ML</given-names></name></person-group><article-title>Symptom improvement in co-occurring PTSD and alcohol dependence</article-title><source>J Nerv Ment Dis</source><year>2006</year><volume>194</volume><fpage>690</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/01.nmd.0000235794.12794.8a</pub-id><pub-id pub-id-type="pmid">16971821</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouimette</surname><given-names>P</given-names></name><name><surname>Read</surname><given-names>JP</given-names></name><name><surname>Wade</surname><given-names>M</given-names></name><name><surname>Tirone</surname><given-names>V</given-names></name></person-group><article-title>Modeling associations between posttraumatic stress symptoms and substance use</article-title><source>Addict Behav</source><year>2010</year><volume>35</volume><fpage>64</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2009.08.009</pub-id><pub-id pub-id-type="pmid">19729250</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saladin</surname><given-names>ME</given-names></name><name><surname>Drobes</surname><given-names>DJ</given-names></name><name><surname>Coffey</surname><given-names>SF</given-names></name><name><surname>Dansky</surname><given-names>BS</given-names></name><name><surname>Brady</surname><given-names>KT</given-names></name><name><surname>Kilpatrick</surname><given-names>DG</given-names></name></person-group><article-title>PTSD symptom severity as a predictor of cue-elicited drug craving in victims of violent crime</article-title><source>Addict Behav</source><year>2003</year><volume>28</volume><fpage>1611</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2003.08.037</pub-id><pub-id pub-id-type="pmid">14656549</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hien</surname><given-names>DA</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>AN</given-names></name><name><surname>Hu</surname><given-names>M-C</given-names></name><name><surname>Miele</surname><given-names>GM</given-names></name><name><surname>Cohen</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA&#x02019;s Clinical Trials Network</article-title><source>Am J Psychiatry</source><year>2009</year><volume>167</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09091261</pub-id><pub-id pub-id-type="pmid">19917596</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldrop</surname><given-names>AE</given-names></name><name><surname>Back</surname><given-names>SE</given-names></name><name><surname>Verduin</surname><given-names>ML</given-names></name><name><surname>Brady</surname><given-names>KT</given-names></name></person-group><article-title>Triggers for cocaine and alcohol use in the presence and absence of posttraumatic stress disorder</article-title><source>Addict Behav</source><year>2007</year><volume>32</volume><fpage>634</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2006.06.001</pub-id><pub-id pub-id-type="pmid">16863682</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Diagnostic and Statistical Manual of Mental Disorders: DSM-5</source><year>2013</year><publisher-loc>Washington, D.C.</publisher-loc><publisher-name>American Psychiatric Association</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spitzer</surname><given-names>C</given-names></name><name><surname>Freyberger</surname><given-names>HJ</given-names></name><name><surname>Stieglitz</surname><given-names>R-D</given-names></name><name><surname>Carlson</surname><given-names>EB</given-names></name><name><surname>Kuhn</surname><given-names>G</given-names></name><name><surname>Magdeburg</surname><given-names>N</given-names></name><etal/></person-group><article-title>Adaptation and psychometric properties of the German version of the dissociative experience scale</article-title><source>J Trauma Stress</source><year>1998</year><volume>11</volume><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1023/A:1024457819547</pub-id><pub-id pub-id-type="pmid">9870230</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Reddemann</surname><given-names>L</given-names></name></person-group><source>Imagination als heilsame Kraft zur Behandlung von Traumafolgen mit ressourcenorientierten Verfahren</source><year>2003</year><edition>8</edition><publisher-loc>Stuttgart</publisher-loc><publisher-name>Klett-Cotta</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AW</given-names></name><name><surname>Linehan</surname><given-names>MM</given-names></name></person-group><article-title>Applications of dialectical behavior therapy to posttraumatic stress disorder and related problems</article-title><source>Cogn Behav Ther Trauma</source><year>2006</year><volume>2</volume><fpage>117</fpage><lpage>145</lpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Najavits</surname><given-names>LM</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>I</given-names></name><name><surname>Stubenvoll</surname><given-names>M</given-names></name><name><surname>Dilling</surname><given-names>A</given-names></name></person-group><source>Posttraumatische Belastungsst&#x000f6;rung und Substanzmissbrauch: Das Therapieprogramm &#x0201c;Sicherheit finden&#x0201d;</source><year>2008</year><edition>1</edition><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>F</given-names></name></person-group><article-title>Eye movement desensitization and reprocessing procedure: from EMD to EMDR: a new treatment model for anxiety and related traumata</article-title><source>Behav Ther</source><year>1991</year><volume>14</volume><fpage>133</fpage><lpage>135</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>F</given-names></name><name><surname>Forrest</surname><given-names>MS</given-names></name></person-group><source>Eye movement desensitization and reprocessing (EMDR): Basic principles, protocols and procedures</source><year>2001</year><publisher-loc>New York</publisher-loc><publisher-name>Guilford Press</publisher-name></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>W</given-names></name><name><surname>Zaudig</surname><given-names>M</given-names></name><name><surname>Mombour</surname><given-names>W</given-names></name></person-group><source>Internationale Diagnosen Checklisten (IDCL) f&#x000fc;r DSM-IV</source><year>1997</year><publisher-loc>G&#x000f6;ttingen</publisher-loc><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiller</surname><given-names>W</given-names></name><name><surname>Zaudig</surname><given-names>M</given-names></name><name><surname>Mombour</surname><given-names>W</given-names></name></person-group><article-title>Development of diagnostic checklists for use in routine clinical care: a guideline designed to assess DSM-III-R diagnoses</article-title><source>Arch Gen Psychiatry</source><year>1990</year><volume>47</volume><fpage>782</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1990.01810200090013</pub-id><pub-id pub-id-type="pmid">2378549</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schnyder</surname><given-names>U</given-names></name></person-group><source>Clinician-Administered PTSD Scale for DSM-5 - Past month version</source><year>2013</year><publisher-loc>Z&#x000fc;rich</publisher-loc><publisher-name>Universit&#x000e4;tsSpital Z&#x000fc;rich</publisher-name></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, Marx BP, Keane TM. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). National Center for PTSD; 2013. Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp">http://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp</ext-link>.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weathers</surname><given-names>FW</given-names></name><name><surname>Keane</surname><given-names>TM</given-names></name><name><surname>Davidson</surname><given-names>JR</given-names></name></person-group><article-title>Clinician-administered PTSD scale: a review of the first ten years of research</article-title><source>Depress Anxiety</source><year>2001</year><volume>13</volume><fpage>132</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/da.1029</pub-id><pub-id pub-id-type="pmid">11387733</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>DS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wilson</surname><given-names>JP</given-names></name><name><surname>Keane</surname><given-names>TM</given-names></name></person-group><article-title>Structured clinical interview techniques for PTSD</article-title><source>Assessing psychological trauma and PTSD</source><year>2004</year><edition>2</edition><publisher-loc>New York</publisher-loc><publisher-name>Guilford Press</publisher-name><fpage>103</fpage><lpage>21</lpage></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dybek</surname><given-names>I</given-names></name><name><surname>Bischof</surname><given-names>G</given-names></name><name><surname>Grothues</surname><given-names>J</given-names></name><name><surname>Reinhardt</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Hapke</surname><given-names>U</given-names></name><etal/></person-group><article-title>The reliability and validity of the alcohol use disorders identification test (AUDIT) in a German general practice population sample</article-title><source>J Stud Alcohol</source><year>2006</year><volume>67</volume><fpage>473</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.15288/jsa.2006.67.473</pub-id><pub-id pub-id-type="pmid">16608159</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>JB</given-names></name><name><surname>Aasland</surname><given-names>OG</given-names></name><name><surname>Babor</surname><given-names>TF</given-names></name><name><surname>De la Fuente</surname><given-names>JR</given-names></name><name><surname>Grant</surname><given-names>M</given-names></name></person-group><article-title>Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II</article-title><source>Addiction</source><year>1993</year><volume>88</volume><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.1993.tb02093.x</pub-id><pub-id pub-id-type="pmid">8329970</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>AH</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Palmstierna</surname><given-names>T</given-names></name><name><surname>Schlyter</surname><given-names>F</given-names></name></person-group><article-title>Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample</article-title><source>Eur Addict Res</source><year>2005</year><volume>11</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1159/000081413</pub-id><pub-id pub-id-type="pmid">15608468</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thormann</surname><given-names>A</given-names></name><name><surname>Schalast</surname><given-names>N</given-names></name></person-group><source>Drug Use Disorders Identification Test (DUDIT)</source><year>2002</year><publisher-loc>Duisburg</publisher-loc><publisher-name>Institute of Forensic Psychiatry, University of Duisburg-Essen</publisher-name></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sobell</surname><given-names>LC</given-names></name><name><surname>Sobell</surname><given-names>MB</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Litten</surname><given-names>RZ</given-names></name><name><surname>Allen</surname><given-names>JP</given-names></name></person-group><article-title>Timeline follow-back: A technique for assessing self-reported alcohol consumption</article-title><source>Measuring alcohol consumption: Psychosocial and biochemical methods</source><year>1992</year><publisher-loc>Totowa</publisher-loc><publisher-name>Humana Press</publisher-name><fpage>41</fpage><lpage>72</lpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McGahan</surname><given-names>PL</given-names></name><name><surname>Griffith</surname><given-names>JA</given-names></name><name><surname>Parente</surname><given-names>R</given-names></name><name><surname>McLellan</surname><given-names>AT</given-names></name></person-group><source>Addiction Severity Index composite scores manual</source><year>1986</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Treatment Research Institute</publisher-name></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hautzinger</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>F</given-names></name><name><surname>K&#x000fc;hner</surname><given-names>C</given-names></name></person-group><source>Beck Depressions-Inventar (BDI-II). Frankfurt am Main</source><year>2006</year><publisher-loc>Germany</publisher-loc><publisher-name>Harcourt Test Services</publisher-name></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gratz</surname><given-names>KL</given-names></name><name><surname>Roemer</surname><given-names>L</given-names></name></person-group><article-title>Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale</article-title><source>J Psychopathol Behav Assess</source><year>2004</year><volume>26</volume><fpage>41</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1023/B:JOBA.0000007455.08539.94</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>SD</given-names></name></person-group><article-title>A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity</article-title><source>Med Care</source><year>1996</year><volume>34</volume><fpage>220</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1097/00005650-199603000-00003</pub-id><pub-id pub-id-type="pmid">8628042</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>DP</given-names></name><name><surname>Stein</surname><given-names>JA</given-names></name><name><surname>Newcomb</surname><given-names>MD</given-names></name><name><surname>Walker</surname><given-names>E</given-names></name><name><surname>Pogge</surname><given-names>D</given-names></name><name><surname>Ahluvalia</surname><given-names>T</given-names></name><etal/></person-group><article-title>Development and validation of a brief screening version of the childhood trauma questionnaire</article-title><source>Child Abuse Negl</source><year>2003</year><volume>27</volume><fpage>169</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0145-2134(02)00541-0</pub-id><pub-id pub-id-type="pmid">12615092</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Deutsche Gesellschaft f&#x000fc;r Suchtforschung und Suchttherapie [German Society for Addiction Research and Therapy]. Dokumentationsstandards III f&#x000fc;r die Evaluation der Behandlung von Abh&#x000e4;ngigen [Documentation standards III for the evaluation of addiction treatment]. Sucht. 2001;47:3&#x02013;94.</mixed-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Missel</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>B</given-names></name><name><surname>Bachmeier</surname><given-names>R</given-names></name><name><surname>Funke</surname><given-names>W</given-names></name><name><surname>Garbe</surname><given-names>D</given-names></name><name><surname>Herder</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effektivit&#x000e4;t der station&#x000e4;ren Suchtrehabilitation &#x02013; FVS-Katamnese des Entlassjahrgangs 2006 von Fachkliniken f&#x000fc;r Alkohol-und Medikamentenabh&#x000e4;ngige</article-title><source>Sucht Aktuell</source><year>2010</year><volume>17</volume><fpage>9</fpage><lpage>20</lpage></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zobel</surname><given-names>M</given-names></name><name><surname>Missel</surname><given-names>P</given-names></name><name><surname>Bachmeier</surname><given-names>R</given-names></name><name><surname>Funke</surname><given-names>W</given-names></name><name><surname>Garbe</surname><given-names>D</given-names></name><name><surname>Herder</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effektivit&#x000e4;t der station&#x000e4;ren Suchtrehabilitation&#x02013;FVS-Katamnese des Entlassjahrgangs 2004 von Fachkliniken f&#x000fc;r Alkohol-und Medikamentenabh&#x000e4;ngige</article-title><source>Sucht Aktuell</source><year>2005</year><volume>12</volume><fpage>5</fpage><lpage>15</lpage></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Korn</surname><given-names>DL</given-names></name><name><surname>Zangwill</surname><given-names>W</given-names></name><name><surname>Lipke</surname><given-names>H</given-names></name><name><surname>Smyth</surname><given-names>NJ</given-names></name></person-group><source>EMDR Implementation Fidelity Scale</source><year>2001</year><publisher-loc>Austin</publisher-loc><publisher-name>EMDRIA</publisher-name></element-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">van Minnen A, Harned MS, Zoellner L, Mills K. Examining potential contraindications for prolonged exposure therapy for PTSD. Eur J Psychotraumatology. 2012;3:18805.</mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry. 2001;158:1184&#x02013;90.</mixed-citation></ref></ref-list></back></article>